- Home
- ZVSA vs QNRX Comparison
ZVSA vs QNRX Comparison
Compare ZVSA & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- QNRX
- Stock Information
- Founded
- ZVSA 2014
- QNRX 2018
- Country
- ZVSA United States
- QNRX United States
- Employees
- ZVSA N/A
- QNRX N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- QNRX Medical/Dental Instruments
- Sector
- ZVSA Health Care
- QNRX Health Care
- Exchange
- ZVSA Nasdaq
- QNRX Nasdaq
- Market Cap
- ZVSA 2.3M
- QNRX 2.1M
- IPO Year
- ZVSA N/A
- QNRX N/A
- Fundamental
- Price
- ZVSA $1.08
- QNRX $0.62
- Analyst Decision
- ZVSA Strong Buy
- QNRX Strong Buy
- Analyst Count
- ZVSA 1
- QNRX 1
- Target Price
- ZVSA $240.00
- QNRX $4.00
- AVG Volume (30 Days)
- ZVSA 3.6M
- QNRX 486.4K
- Earning Date
- ZVSA 11-14-2024
- QNRX 11-07-2024
- Dividend Yield
- ZVSA N/A
- QNRX N/A
- EPS Growth
- ZVSA N/A
- QNRX N/A
- EPS
- ZVSA N/A
- QNRX N/A
- Revenue
- ZVSA N/A
- QNRX N/A
- Revenue This Year
- ZVSA N/A
- QNRX N/A
- Revenue Next Year
- ZVSA N/A
- QNRX N/A
- P/E Ratio
- ZVSA N/A
- QNRX N/A
- Revenue Growth
- ZVSA N/A
- QNRX N/A
- 52 Week Low
- ZVSA $1.05
- QNRX $0.48
- 52 Week High
- ZVSA $42.35
- QNRX $6.18
- Technical
- Relative Strength Index (RSI)
- ZVSA 27.91
- QNRX 43.57
- Support Level
- ZVSA $1.34
- QNRX $0.60
- Resistance Level
- ZVSA $1.89
- QNRX $0.77
- Average True Range (ATR)
- ZVSA 0.25
- QNRX 0.07
- MACD
- ZVSA -0.08
- QNRX -0.02
- Stochastic Oscillator
- ZVSA 1.29
- QNRX 12.98
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.